Alpha9 Theranostics develops peptide-based radiopharmaceuticals for the targeted treatment of solid and hematologic malignancies. Their technology aims to improve therapeutic precision and efficacy, addressing the limitations of conventional cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional cancer therapies often lack the precision needed to target malignant cells effectively, leading to systemic toxicity and suboptimal therapeutic outcomes for patients with solid and hematologic malignancies. Traditional approaches may not adequately reach or penetrate tumor sites, limiting their efficacy in treating advanced or metastatic cancers.
Solution
Alpha9 Theranostics is developing a pipeline of peptide-based radiopharmaceuticals designed for targeted cancer treatment. These engineered molecules selectively bind to cancer cells, delivering radiation directly to the tumor site while minimizing damage to healthy tissues. By leveraging a bespoke, iterative approach to radiotherapeutic design, Alpha9 aims to improve therapeutic precision and efficacy across a range of solid and hematologic malignancies. The company's radiopharmaceuticals are intended to address the limitations of conventional therapies by enhancing tumor penetration and reducing off-target effects.
Target Audience
The primary target audience includes patients with solid and hematologic malignancies, as well as oncologists and medical professionals seeking more precise and effective cancer treatment options.
Features
- Peptide-based radiopharmaceuticals for targeted delivery of radiation to cancer cells
- Bespoke, iterative design approach to optimize therapeutic efficacy
- Pipeline of radiopharmaceuticals targeting various solid and hematologic malignancies